EcoDrugPlus

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSDCDG00000004359
Gene Symbol: LOC114798783
3 Cross references
202 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSDCDG00000024047
Gene Symbol: LOC114800076
3 Cross references
202 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSDCDG00000004288
Gene Symbol: CACNA1SB
1 Cross references
196 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1s Subunit, B

Ensembl ID : ENSDCDG00000023598
Gene Symbol: CACNA1SB
1 Cross references
194 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSDCDG00000023692
Gene Symbol: CASR
3 Cross references
203 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSDCDG00000032056
Gene Symbol: CACNA2D1
3 Cross references
229 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSDCDG00000002490
Gene Symbol: CACNA2D2
3 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSDCDG00000030119
Gene Symbol: CACNA2D2
3 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSDCDG00000007704
Gene Symbol: CACNA2D3
3 Cross references
217 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSDCDG00000034958
Gene Symbol: CACNA2D4
1 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSDCDG00000034049
Gene Symbol: CACNA2D4
3 Cross references
233 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 1

Ensembl ID : ENSDCDG00000026510
Gene Symbol: CACNB1
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).